Spinal Cord Injury - Pipeline Review, H2 2015

Published: Aug, 2015 | Pages: 225 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Summary

Global Markets Direct's, 'Spinal cord Injury - Pipeline Review, H2 2015', provides an overview of the Spinal cord Injury's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Spinal cord Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal cord Injury and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Spinal cord Injury
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Spinal cord Injury and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Spinal cord Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Spinal cord Injury pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Spinal cord Injury
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Spinal cord Injury pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Spinal Cord Injury Overview 9
Therapeutics Development 10
Pipeline Products for Spinal Cord Injury - Overview 10
Pipeline Products for Spinal Cord Injury - Comparative Analysis 11
Spinal Cord Injury - Therapeutics under Development by Companies 12
Spinal Cord Injury - Therapeutics under Investigation by Universities/Institutes 16
Spinal Cord Injury - Pipeline Products Glance 17
Clinical Stage Products 17
Early Stage Products 18
Spinal Cord Injury - Products under Development by Companies 19
Spinal Cord Injury - Products under Investigation by Universities/Institutes 23
Spinal Cord Injury - Companies Involved in Therapeutics Development 25
Acorda Therapeutics, Inc. 25
Asubio Pharma Co., Ltd. 26
Athersys, Inc. 27
Axerion Therapeutics, Inc. 28
BioArctic Neuroscience AB 29
Cortex Pharmaceuticals, Inc. 30
Faron Pharmaceuticals Oy 31
FirstString Research, Inc. 32
Genervon Biopharmaceuticals, LLC 33
Grupo Ferrer Internacional, S.A. 34
Hemostemix Ltd 35
Histocell S.L. 36
K-Stemcell Co., Ltd. 37
Kadimastem Ltd. 38
Kringle Pharma, Inc. 39
Lipopharma Therapeutics SL 40
Lpath, Inc. 41
MandalMed, Inc. 42
Mapreg S.A.S. 43
Mitsubishi Tanabe Pharma Corporation 44
Neuralstem, Inc. 45
Neuronax SAS 46
Omeros Corporation 47
PharmatrophiX, Inc. 48
Pharmicell Co., Ltd. 49
Q Therapeutics, Inc. 50
Quark Pharmaceuticals, Inc. 51
Remedy Pharmaceuticals, Inc. 52
RhinoCyte, Inc. 53
SanBio, Inc. 54
Sirnaomics, Inc. 55
StemCells, Inc. 56
Stemedica Cell Technologies, Inc. 57
TissueGene, Inc. 58
Vertex Pharmaceuticals Incorporated 59
Vicore Pharma AB 60
Spinal Cord Injury - Therapeutics Assessment 61
Assessment by Monotherapy Products 61
Assessment by Combination Products 62
Assessment by Target 63
Assessment by Mechanism of Action 66
Assessment by Route of Administration 68
Assessment by Molecule Type 70
Drug Profiles 72
(buspirone + levodopa + carbidopa) - Drug Profile 72
ACTX-08 - Drug Profile 73
Antibody to Inhibit RGM for Spinal Cord Injury - Drug Profile 74
AP-325 - Drug Profile 75
AST-OPC-1 - Drug Profile 76
Astrostem - Drug Profile 78
AX-007 - Drug Profile 79
BA-277 - Drug Profile 80
BA-434 - Drug Profile 81
C-21 - Drug Profile 82
Cell Therapy for Spinal Cord Injury - Drug Profile 84
Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury - Drug Profile 85
Cerecellgram-Spine - Drug Profile 87
CHEC-7 - Drug Profile 88
CHEC-9 - Drug Profile 89
chondroitinase ABC nanosphere - Drug Profile 91
cimaglermin alfa - Drug Profile 92
CLR-01 - Drug Profile 94
CM-101 - Drug Profile 95
CX-1739 - Drug Profile 96
CX-717 - Drug Profile 98
Drug for Spinal Cord Injury - Drug Profile 100
Enzyme to Inhibit Chondroitin Sulfate Proteoglycan for Spinal Cord Injury and Brain Injury - Drug Profile 101
FIB-117 - Drug Profile 102
glyburide - Drug Profile 103
GM-603 - Drug Profile 105
HBN-1 - Drug Profile 106
HC-016 - Drug Profile 107
HuCNS-SC - Drug Profile 108
ICCN-100 - Drug Profile 110
IMS-001 - Drug Profile 111
IMS-002 - Drug Profile 112
interferon beta-1a - Drug Profile 113
KP-100IT - Drug Profile 115
LM11A-31 - Drug Profile 117
LPA-181 - Drug Profile 118
Lpathomab - Drug Profile 119
MAP-4343 - Drug Profile 120
MultiStem - Drug Profile 121
NCP-01 - Drug Profile 125
Neural Stem Cells - Drug Profile 126
neurovitas - Drug Profile 128
NgR(310)ecto-Fc - Drug Profile 129
NSI-566 - Drug Profile 131
NX-210 - Drug Profile 133
Oligonucleotide for Central Nervous System and Metabolic Disorders - Drug Profile 134
Peptide to Inhibit Ephrin-A for ALS and Acute Spinal Cord Injury - Drug Profile 135
Peptides for Central Nervous System and Musculoskeletal Disorders - Drug Profile 136
PT-00114 - Drug Profile 137
Q-Cells - Drug Profile 138
Recombinant Protein for Spinal Cord Injury - Drug Profile 140
SB-618 - Drug Profile 141
SB-623 - Drug Profile 142
SC-0806 - Drug Profile 144
siRNA for CNS Disorders - Drug Profile 146
Small Molecule to Antagonize GPR17 for Central Nervous System Disorders - Drug Profile 147
Small Molecules for Spinal Cord Injury - Drug Profile 148
Stem Cell Therapy for Acute Spinal Cord Injury - Drug Profile 149
Stem Cell Therapy for CNS Disorders - Drug Profile 150
Stem Cell Therapy for Neurodegenerative Disorders - Drug Profile 151
Stem Cell Therapy for Spinal Cord Injury - Drug Profile 153
Stem Cell Therapy for Spinal Cord Injury - Drug Profile 154
Stem Cell Therapy Program for Neurodegenerative Diseases - Drug Profile 155
STP-805 - Drug Profile 156
SUN-13837 - Drug Profile 157
Synthetic Peptide for Spinal Cord Injuries - Drug Profile 158
Synthetic Peptide to Antagonize PTPRS for Spinal Cord Injury - Drug Profile 159
Synthetic Peptides to Activate SDF-1 Alpha for CNS Disorders and Infectious Disease - Drug Profile 160
Tenascin-C Fragments for Spinal Cord Injury - Drug Profile 161
TG-N - Drug Profile 163
UH-0113 - Drug Profile 164
UH-0213 - Drug Profile 165
VX-210 - Drug Profile 166
Spinal Cord Injury - Recent Pipeline Updates 169
Spinal Cord Injury - Dormant Projects 206
Spinal Cord Injury - Discontinued Products 208
Spinal Cord Injury - Product Development Milestones 209
Featured News & Press Releases 209

Appendix 219
Methodology 219
Coverage 219
Secondary Research 219
Primary Research 219
Expert Panel Validation 219
Contact Us 219
Disclaimer 220

List of Tables

Number of Products under Development for Spinal Cord Injury, H2 2015 15
Number of Products under Development for Spinal Cord Injury - Comparative Analysis, H2 2015 16
Number of Products under Development by Companies, H2 2015 18
Number of Products under Development by Companies, H2 2015 (Contd..1) 19
Number of Products under Development by Companies, H2 2015 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H2 2015 21
Comparative Analysis by Clinical Stage Development, H2 2015 22
Comparative Analysis by Early Stage Development, H2 2015 23
Products under Development by Companies, H2 2015 24
Products under Development by Companies, H2 2015 (Contd..1) 25
Products under Development by Companies, H2 2015 (Contd..2) 26
Products under Development by Companies, H2 2015 (Contd..3) 27
Products under Investigation by Universities/Institutes, H2 2015 28
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 29
Spinal Cord Injury - Pipeline by Acorda Therapeutics, Inc., H2 2015 30
Spinal Cord Injury - Pipeline by Asubio Pharma Co., Ltd., H2 2015 31
Spinal Cord Injury - Pipeline by Athersys, Inc., H2 2015 32
Spinal Cord Injury - Pipeline by Axerion Therapeutics, Inc., H2 2015 33
Spinal Cord Injury - Pipeline by BioArctic Neuroscience AB, H2 2015 34
Spinal Cord Injury - Pipeline by Cortex Pharmaceuticals, Inc., H2 2015 35
Spinal Cord Injury - Pipeline by Faron Pharmaceuticals Oy, H2 2015 36
Spinal Cord Injury - Pipeline by FirstString Research, Inc., H2 2015 37
Spinal Cord Injury - Pipeline by Genervon Biopharmaceuticals, LLC, H2 2015 38
Spinal Cord Injury - Pipeline by Grupo Ferrer Internacional, S.A., H2 2015 39
Spinal Cord Injury - Pipeline by Hemostemix Ltd, H2 2015 40
Spinal Cord Injury - Pipeline by Histocell S.L., H2 2015 41
Spinal Cord Injury - Pipeline by K-Stemcell Co., Ltd., H2 2015 42
Spinal Cord Injury - Pipeline by Kadimastem Ltd., H2 2015 43
Spinal Cord Injury - Pipeline by Kringle Pharma, Inc., H2 2015 44
Spinal Cord Injury - Pipeline by Lipopharma Therapeutics SL, H2 2015 45
Spinal Cord Injury - Pipeline by Lpath, Inc., H2 2015 46
Spinal Cord Injury - Pipeline by MandalMed, Inc., H2 2015 47
Spinal Cord Injury - Pipeline by Mapreg S.A.S., H2 2015 48
Spinal Cord Injury - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015 49
Spinal Cord Injury - Pipeline by Neuralstem, Inc., H2 2015 50
Spinal Cord Injury - Pipeline by Neuronax SAS, H2 2015 51
Spinal Cord Injury - Pipeline by Omeros Corporation, H2 2015 52
Spinal Cord Injury - Pipeline by PharmatrophiX, Inc., H2 2015 53
Spinal Cord Injury - Pipeline by Pharmicell Co., Ltd., H2 2015 54
Spinal Cord Injury - Pipeline by Q Therapeutics, Inc., H2 2015 55
Spinal Cord Injury - Pipeline by Quark Pharmaceuticals, Inc., H2 2015 56
Spinal Cord Injury - Pipeline by Remedy Pharmaceuticals, Inc., H2 2015 57
Spinal Cord Injury - Pipeline by RhinoCyte, Inc., H2 2015 58
Spinal Cord Injury - Pipeline by SanBio, Inc., H2 2015 59
Spinal Cord Injury - Pipeline by Sirnaomics, Inc., H2 2015 60
Spinal Cord Injury - Pipeline by StemCells, Inc., H2 2015 61
Spinal Cord Injury - Pipeline by Stemedica Cell Technologies, Inc., H2 2015 62
Spinal Cord Injury - Pipeline by TissueGene, Inc., H2 2015 63
Spinal Cord Injury - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2015 64
Spinal Cord Injury - Pipeline by Vicore Pharma AB, H2 2015 65
Assessment by Monotherapy Products, H2 2015 66
Assessment by Combination Products, H2 2015 67
Number of Products by Stage and Target, H2 2015 69
Number of Products by Stage and Mechanism of Action, H2 2015 72
Number of Products by Stage and Route of Administration, H2 2015 74
Number of Products by Stage and Molecule Type, H2 2015 76
Spinal Cord Injury Therapeutics - Recent Pipeline Updates, H2 2015 174
Spinal Cord Injury - Dormant Projects, H2 2015 211
Spinal Cord Injury - Dormant Projects (Contd..2), H2 2015 212
Spinal Cord Injury - Discontinued Products, H2 2015 213